Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · HCA Healthcare (HCA)

HCA Healthcare adopts 2026 executive bonus program tied to EBITDA and quality metrics

Neutral Impact 2 of 5 leadership Written later

HCA Healthcare's Compensation Committee adopted a 2026 Executive Officer Performance Excellence Program on February 24, 2026, setting cash bonus targets for named executives, including 175% of base salary for CEO Samuel N. Hazen. Separately, director Robert J. Dennis said he will retire from the board at the April 23, 2026 annual meeting. The filing does not report financial results, so the bonus plan's effect on shareholders depends on the performance targets, which are defined in the plan document.

Key points

  • Awards are weighted 80% on EBITDA targets and 20% on quality metrics, paid solely in cash.
  • Target 2026 awards: 175% of base salary for CEO Samuel N. Hazen; 125% for CFO Michael A. Marks and COO Jon M. Foster; 100% for Michael R. McAlevey and Michael S. Cuffe, M.D.
  • Robert J. Dennis, who informed the company on February 20, 2026, will retire from the board effective April 23, 2026.

The filing

CompanyHCA Healthcare (HCA)
Form8-K, current report
Filed with the SECFeb 25, 2026, 4:43 PM ET
Accession number0001193125-26-071880

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.